Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
University of Utah
Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?
Answer from: Medical Oncologist at Community Practice
I would
Sign In
or
Register
to read more
5507
Related Questions
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Do you make dose modifications to KEYNOTE-522 regimen in the elderly?
What are your top takeaways in Breast Cancer from ASCO 2025?
How are you considering use of inavolisib/palbociclib/fulvestrant over ET doublets for patients with high risk disease features such as visceral metastases, visceral crisis, high tumor burden?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?
Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?